An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.

• Asıl Yazarlar: Taniawati Supali (Yazar), Yenny Djuardi (Yazar), Michael Christian (Yazar), Elisa Iskandar (Yazar), Rahmat Alfian (Yazar), Roospita Maylasari (Yazar), Yossi Destani (Yazar), Adriani Lomiga (Yazar), Dominikus Minggu (Yazar), Daphne Lew (Yazar), Joshua Bogus (Yazar), Gary J Weil (Yazar), Peter U Fischer (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Public Library of Science (PLoS), 2021-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearanc...